KMT2A and leukemia: To understand the mechanism behind the MLL-AF6 specific anti-leukemia activity of thioridazine, the authors used a large-scale method combining quantitative proteomics with affinity enrichment and identified the calcium binding proteins S100A8 and S100A9, and ANXA6, a component of the annexin family, as targets of thioridazine.